Alnylam Pharmaceuticals (NASDAQ:ALNY) just reported results for the first quarter of 2024.
- Alnylam Pharmaceuticals reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -$1.18.
- The company reported revenue of $494.33 million.
- This was 15.68% better than the analyst estimate for revenue of $427.33 million.